A110 ADVANCES IN THORACIC ONCOLOGIC DIAGNOSTICS: Feasibility Of Pd-L1 Expression Testing In Non-Small Cell Lung Cancer From Ebus-Tbna Samples

Rationale: Inhibition of immune checkpoints in the treatment of non-small cell lung cancer (NSCLC) has shown promising results, including targeted therapy against programmed death ligand 1 (PD-L1). Prior studies have shown staining by immunohistochemistry (IHC) on histologic specimens of ≥50% of tum...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 195
Main Authors Lee, J M, Kim, J S, Heymann, J J, Pagan, C, Crapanzano, J P, Fazlollahi, L, Haghighi, M, Stoopler, M B, Sonett, J R, Sacher, A G, Shu, C A, Rizvi, N A, Bulman, W A, Saqi, A
Format Journal Article
LanguageEnglish
Published New York American Thoracic Society 01.01.2017
Subjects
Cellular biology
Lung cancer
Medical diagnosis
Online AccessGet full text

Cover

More Information
Summary:Rationale: Inhibition of immune checkpoints in the treatment of non-small cell lung cancer (NSCLC) has shown promising results, including targeted therapy against programmed death ligand 1 (PD-L1). Prior studies have shown staining by immunohistochemistry (IHC) on histologic specimens of ≥50% of tumor cells predicts benefit with PD-L1 immunotherapy.
ISSN:1073-449X
1535-4970